309 related articles for article (PubMed ID: 34287841)
1. Safety and efficacy of Direct Oral Anticoagulants in cerebral venous thrombosis: A meta-analysis.
Nepal G; Kharel S; Bhagat R; Ka Shing Y; Ariel Coghlan M; Poudyal P; Ojha R; Sunder Shrestha G
Acta Neurol Scand; 2022 Jan; 145(1):10-23. PubMed ID: 34287841
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
3. Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis.
Lee GKH; Chen VH; Tan CH; Leow AST; Kong WY; Sia CH; Chew NWS; Tu TM; Chan BPL; Yeo LLL; Sharma VK; Tan BYQ
J Thromb Thrombolysis; 2020 Oct; 50(3):724-731. PubMed ID: 32279216
[TBL] [Abstract][Full Text] [Related]
4. Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis.
Lurkin A; Derex L; Fambrini A; Bertoletti L; Epinat M; Mismetti P; Dargaud Y
Cerebrovasc Dis; 2019; 48(1-2):32-37. PubMed ID: 31480062
[TBL] [Abstract][Full Text] [Related]
5. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study.
Yaghi S; Shu L; Bakradze E; Salehi Omran S; Giles JA; Amar JY; Henninger N; Elnazeir M; Liberman AL; Moncrieffe K; Lu J; Sharma R; Cheng Y; Zubair AS; Simpkins AN; Li GT; Kung JC; Perez D; Heldner M; Scutelnic A; Seiffge D; Siepen B; Rothstein A; Khazaal O; Do D; Kasab SA; Rahman LA; Mistry EA; Kerrigan D; Lafever H; Nguyen TN; Klein P; Aparicio H; Frontera J; Kuohn L; Agarwal S; Stretz C; Kala N; El Jamal S; Chang A; Cutting S; Xiao H; de Havenon A; Muddasani V; Wu T; Wilson D; Nouh A; Asad SD; Qureshi A; Moore J; Khatri P; Aziz Y; Casteigne B; Khan M; Cheng Y; Mac Grory B; Weiss M; Ryan D; Vedovati MC; Paciaroni M; Siegler JE; Kamen S; Yu S; Leon Guerrero CR; Atallah E; De Marchis GM; Brehm A; Dittrich T; Psychogios M; Alvarado-Dyer R; Kass-Hout T; Prabhakaran S; Honda T; Liebeskind DS; Furie K
Stroke; 2022 Mar; 53(3):728-738. PubMed ID: 35143325
[TBL] [Abstract][Full Text] [Related]
6. Apixaban for the treatment of cerebral venous thrombosis: A case series.
Rao SK; Ibrahim M; Hanni CM; Suchdev K; Parker D; Rajamani K; Mohamed W
J Neurol Sci; 2017 Oct; 381():318-320. PubMed ID: 28991706
[TBL] [Abstract][Full Text] [Related]
7. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
[TBL] [Abstract][Full Text] [Related]
8. Non-Vitamin K Antagonist Oral Anticoagulants for the Treatment of Cerebral Venous Sinus Thrombosis: a Retrospective, Matched Cohort Analysis.
Giles JA; Balasetti VKS; Zazulia AR
Neurocrit Care; 2021 Dec; 35(3):783-788. PubMed ID: 34046861
[TBL] [Abstract][Full Text] [Related]
9. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis.
Yaghi S; Saldanha IJ; Misquith C; Zaidat B; Shah A; Joudi K; Persaud B; Abdul Khalek F; Shu L; de Havenon A; Mistry EA; Bakradze E; Goldstein ED; Reagan J; Theodorou A; Palaiodimou L; Furie K; Field TS; Tsivgoulis G; Mac Grory B
Stroke; 2022 Oct; 53(10):3014-3024. PubMed ID: 35938419
[TBL] [Abstract][Full Text] [Related]
10. Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
Mitrovic D; Emmens W; Naimi A; van der Mijle A; Veeger N; van Roon E; van den Bemt P
Clin Drug Investig; 2022 Jul; 42(7):593-598. PubMed ID: 35675030
[TBL] [Abstract][Full Text] [Related]
11. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
Darius H
Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
[TBL] [Abstract][Full Text] [Related]
12. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
13. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Leung TS; Law EH
Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France.
Bertoletti L; Gusto G; Khachatryan A; Quignot N; Chaves J; Moniot A; Mokgokong R
Thromb Haemost; 2022 Aug; 122(8):1384-1396. PubMed ID: 34983073
[TBL] [Abstract][Full Text] [Related]
15. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Finks SW; Trujillo TC; Dobesh PP
Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Direct Oral Anticoagulants in Cerebral Venous Thrombosis: Meta-Analysis of Randomized Clinical Trials.
Chen X; Guo L; Lin M
Clin Appl Thromb Hemost; 2024; 30():10760296241256360. PubMed ID: 38772568
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of anticoagulation in cerebral vein thrombosis: A systematic review and meta-analysis.
Al Rawahi B; Almegren M; Carrier M
Thromb Res; 2018 Sep; 169():135-139. PubMed ID: 30056293
[TBL] [Abstract][Full Text] [Related]
18. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Stewart M
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
